Latest News
All Times Eastern
- ‘It’s caused a lot of tension in our marriage’: My wife’s family comes visit, hides food and never cleans up. How do we get rid of them?
- Barron's China’s AI Clout Might Be Overstated. What to Know.
- Barron's This Company Makes Costco and Amazon’s Store Brands. Its Stock Is a Buy.
- Barron's This Carbon-Capture Stock Has Big Plans. Why It’s a Buy.
- Barron's Forget Apple and Nvidia. Why June Belongs to Small-Caps.
- Barron's Market Gains as Wall of Worry Crumbles. What Happens Next.
- Judge in FTX bankruptcy rejects media challenge, says customer names can remain secret
- Barron's Commercial Traders Are Net Long Copper. That’s a Good Sign for the Red Metal.
- Mark Zuckerberg says Meta may be ‘primary beneficiary’ of Apple Vision Pro headset
- Biogen stock rallies after full-day halt as FDA panel recommends Alzheimer’s drug for approval
to be replaced
Marker Therapeutics Inc.
MRKRUS
$
0.01
0.40%
After Hours
$
2.5200
After Hours Volume:
9.54K
| Close | Chg | Chg % |
|---|---|---|
| $2.5100 | 0.4300 | 20.67% |
Volume: 560.47K
65 Day Avg: 776.75K
2.1200
Day Range
2.6000
0.6706
52 Week Range
6.6000
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
MRKR Overview
Key Data
- Open $2.2700
- Day Range 2.1200 - 2.6000
- 52 Week Range 0.6706 - 6.6000
- Market Cap $18.3M
- Shares Outstanding 8.8M
- Public Float 6.32M
- Beta 1.13
- Rev. per Employee $179.47K
- P/E Ratio N/A
- EPS -$2.9623
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 78.85K 05/31/23
- % of Float Shorted 1.25%
- Average Volume 776.75K
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 1
Full Ratings
Recent News
Corrected FDA grants emergency authorization to two blood purification systems
The Food and Drug Administration (FDA) on Friday issued emergency use authorizations to blood purification devices manufactured by Terumo Corp. and Marker Therapeutics AG in response to the COVID-19 pandemic. Terumo is a ...
Energy Resolute Energy’s Resolve
Director of Marker Therapeutics Makes $249K Buy
on Benzinga.com
Marker Therapeutics Director Awarded $19K Worth of Stock Options
on Benzinga.com
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
on InvestorPlace.com
Crude Oil Down 2%; Donaldson Shares Drop Following Q3 Results
on Benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
on Benzinga.com
MARK Stock Alert: AI News Causes Volatility for Remark Shares
on InvestorPlace.com
Nasdaq Down 100 Points; Advance Auto Parts Earnings Miss Views
on Benzinga.com
Why Is Marker Therapeutics (MRKR) Stock Up 27% Today?
on InvestorPlace.com
MRKR Soars on Promising MT-601 Data in Lymphoma
on TipRanks.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
on Benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
on Benzinga.com
12 Health Care Stocks Moving In Monday's Pre-Market Session
on Benzinga.com
12 Health Care Stocks Moving In Thursday's Intraday Session
on Benzinga.com
12 Health Care Stocks Moving In Wednesday's Intraday Session
on Benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
on Benzinga.com
Marker Therapeutics Inc.
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company was founded on October 22, 1991 and is headquartered in Houston, TX.